Tips on how to manage your PhD stipend FIND OUT MORE
Martin Luther University of Halle-Wittenberg Featured PhD Programmes
University of Leeds Featured PhD Programmes

Stereospecific Suzuki-Miyaura Csp3-Csp2 Cross-Coupling of Saturated Heterocyclic Boronates: Programmable Exploration of 3-D Space, EPSRC iCASE with AstraZeneca


Department of Chemistry

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
Prof P O'Brien , Prof I J S Fairlamb No more applications being accepted Funded PhD Project (Students Worldwide)
York United Kingdom Organic Chemistry Pharmaceutical Chemistry Synthetic Chemistry

About the Project

Background

A long-standing and ongoing fundamental challenge in cross-coupling chemistry is the formation of stereodefined carbon-carbon bonds using Csp3-Csp2 Suzuki-Miyaura cross-coupling.[1,2] Secondary, enantiopure alkyl boron reagents are readily accessible, bench-stable and configurationally stable, and thus can be considered as the ideal cross-coupling partners – the pre-installed stereochemistry can be perfectly translated into the targeted products. However, whilst there have been notable stereospecific Suzuki-Miyaura cross-coupling successes with acyclic alkyl boron reagents,[3-5] the analogous reactions with cyclic systems have been far more challenging to develop[4,5] – and this topic will be directly addressed in this project, with the focus on 3-D pharmaceutically-relevant saturated nitrogen and oxygen heterocycles.

Objectives

1. Optimisation of Suzuki-Miyaura cross-coupling of oxygen/nitrogen saturated heterocycles using high throughput experimentation, rich data analysis and ligand design

2. Exploration of the scope of the Suzuki-Miyaura cross-coupling of oxygen/nitrogen saturated heterocycles (boronates and aryl halides)

3. Applications to analogue and library synthesis including elaboration of fragment hits (including covid-19 proteins)

Experimental Approach

In this project which will be carried out in collaboration with AstraZeneca, we will synthesise bench-stable, stereodefined, enantiopure heterocyclic alkyl boronate building blocks and deploy them in stereospecific Csp3-Csp2 Suzuki-Miyaura cross-coupling reactions. The pharmaceutical industry has specifically highlighted the need for a general stereoselective method: “With the success of the Suzuki-Miyaura coupling reaction in generating biaryl motifs, a variant allowing routine sp3–sp2 and sp3–sp3 couplings – ideally in an enantioselective manner – is both highly desirable and could fundamentally change the motifs being generated.”[6] This is one of the last remaining problems to solve in cross-coupling chemistry – it is our conjecture that the key to unlocking the potential of such reactions is a combination of high throughput experimentation, statistical analysis of rich data and in-depth mechanistic studies. Given the ubiquity of cyclic molecules containing stereodefined Csp3-Csp2 bonds in FDA-approved drugs, the process could become an enabling and transformative technology for use within medicinal chemistry programmes. The methods will also be used for the synthesis of libraries of elaborated fragments from fragment hits generated against covid-19 proteins.[7,8]

Novelty

There is currently no method for the general stereospecific Csp3-Csp2 Suzuki-Miyaura cross-coupling of enantiopure saturated heterocyclic boronates with aryl halides. This project aims to deliver such a process to enable non-traditional disconnections, fundamentally changing the way that three-dimensional saturated nitrogen and oxygen heterocycles can be constructed.

Training

This project will provide state-of-the-art training in modern synthetic methodology and medicinal chemistry, including a placement at AstraZeneca. The graduating PhD student will be fully equipped for a future career in the pharmaceutical industry. All Chemistry research students have access to our innovative Doctoral Training in Chemistry (iDTC): cohort-based training to support the development of scientific, transferable and employability skill.

The Department of Chemistry holds an Athena SWAN Gold Award and is committed to supporting equality and diversity for all staff and students. The Department strives to provide a working environment which allows all staff and students to contribute fully, to flourish, and to excel: https://www.york.ac.uk/chemistry/ed/.

You should hold or expect to achieve the equivalent of at least a UK upper second class degree in Chemistry or a related subject.  Please check the entry requirements for your country: https://www.york.ac.uk/study/international/your-country/

For more information about the project, click on the supervisor's name above to email the supervisor. For more information about the application process or funding, please click on email institution

This PhD will formally start on 1 October 2021. Induction activities will start on 27 September.


Funding Notes

This project is funded by an EPSRC iCASE with AstraZeneca. Appointed candidates will be fully-funded for 4 years. The funding includes:
 Tax-free annual “UKRI level” stipend (£15,285 full time for 2020/21)
 UK tuition fees (£4,473 for 2021/22)
 Research support and training charges
International candidates (including EU) may be considered, however the fee difference would need to be covered from other sources. International tuition fees for 2021 entry are £22,250

References

1. Reisman, S. E. et al. Chem. Rev. 2015, 115, 9587.
2. Rygus, J. P. G.; Crudden, C. M. J. Am. Chem. Soc. 2017, 139, 18124.
3. Crudden, C. M. et al. J. Am. Chem. Soc. 2009, 131, 5024.
4. Sigman, M. S.; Biscoe, M. R. et al. Science 2018, 362, 670.
5. Burke, M. D. et al. Nat. Commun. 2019, 10, 1263.
6. Blakemore, D. C. et al. A. Nat. Chem. 2018, 10, 383.
7. https://www.diamond.ac.uk/covid-19/for-scientists/Main-protease-structure-and-XChem.html
8. https://www.diamond.ac.uk/covid-19/for-scientists/NSP3-macrodomain-structure-and-XChem.html


FindAPhD. Copyright 2005-2021
All rights reserved.